Literature DB >> 1532406

Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats.

S F Queener1, R A Dean, M S Bartlett, W K Milhous, J D Berman, W Y Ellis, J W Smith.   

Abstract

Experimental 8-aminoquinolines from Walter Reed Army Institute for Research are effective for prophylaxis or therapy of Pneumocystis carinii pneumonia in rat models. In the present study, primaquine, WR6026, and WR238605 were tested in prophylaxis and treatment models of P. carinii pneumonia to compare the effectiveness of continuous versus intermittent dosing. For treatment of P. carinii pneumonia, the drugs showed detectable effects when given once every 4 days (primaquine and WR6026 at doses greater than 8 mg/kg; WR238605 at doses greater than 2 mg/kg). For prophylaxis, WR6026 and WR238605 were effective given alone daily (WR6026 at doses greater than 0.25 mg/kg; WR238605 at doses greater than 0.57 mg/kg). WR6026 and WR238605 at 4 mg/kg given once every 4 days for prophylaxis were as effective as daily trimethoprim-sulfamethoxazole. These studies suggest that higher doses of 8-aminoquinolines administered at appropriate intervals may be as effective as continuous dosing for prophylaxis of P. carinii pneumonia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532406     DOI: 10.1093/infdis/165.4.764

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Tafenoquine: A Step toward Malaria Elimination.

Authors:  Kuan-Yi Lu; Emily R Derbyshire
Journal:  Biochemistry       Date:  2020-02-24       Impact factor: 3.162

2.  Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.

Authors:  M D Ball; M S Bartlett; M Shaw; J W Smith; M Nasr; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

4.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

5.  Tafenoquine exhibits broad spectrum antifungal activity at clinically relevant concentrations in vitro and decreases lung fungal burden in an invasive pulmonary model of Rhizopus in vivo.

Authors:  G Dow; B Smith
Journal:  New Microbes New Infect       Date:  2022-02-04

6.  Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.

Authors:  Qigui Li; Michael O'Neil; Lisa Xie; Diana Caridha; Qiang Zeng; Jing Zhang; Brandon Pybus; Mark Hickman; Victor Melendez
Journal:  Malar J       Date:  2014-04-14       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.